The recognition of HIV-1 consensus group M Gag and Nef peptide reagents in mono- and multi-clade epidemics: implications for HIV vaccine design
© Zembe et al; licensee BioMed Central Ltd. 2012
Published: 13 September 2012
The high level of genetic diversity of HIV-1 poses a major challenge for global vaccine development. Vaccines based on centralized sequences would minimize genetic distances to multiple clades and potentially maximize cross-reactivity. Whether reactivity of these centralized peptide reagents differs in mono- and multi-clade epidemic is unknown.
In this study, full-length gag and nef gene sequences (from Cameroon, 50 and 54, respectively and South Africa, 23 and 19, respectively) were characterized. HIV-specific T-cell responses to group M consensus Gag and Nef peptide reagents were characterized at the peptide level using the IFN-γ ELISpot assay.
Viruses from Cameron exhibited a large degree of genetic diversity; all subtypes were present excluding subtype C, with CRF02_AG being dominating (49%). Contrary, sequenced viruses from South Africa were all pure subtype C viruses. Despite the greater diversity of viral clades in the Cameroonian cohort, the genetic distances to the consensus M reagents was similar for both cohorts (11% and 15% for Gag and Nef, respectively). Whilst the magnitude and breadth of responses to Con M Gag and Nef did not differ significantly between the two cohorts, there was a greater frequency of responders in the Cameroonian cohort compared to South Africans (95% versus 82%, respectively). For the Cameroonian cohort, 75/182 (41%) of the consensus M peptides were targeted, while for the South African cohort 66/182 (36%) of the peptides were targeted, with the majority being recognized in only 1-2 participants (69% and 76%, respectively). Patterns of immunodominance and targeting, however, differed dramatically between the two cohorts, with only 36% and 39% of Gag and Nef peptides commonly recognized between the two cohorts.
Although similarities in total magnitude and breadth may be observed between different epidemics, patterns of immunodominance of centralized immunogens may be different which may have implications for vaccine development.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.